Riskpilot← Back to searchSign inGet full accessDelavaran Group AB
ABIn liquidationOrg 5568799646General medical practice activities · NACE 8621Est. 20120 employees
Revenue 2024
—
EBITDA margin
—
-17% vs 2023
Equity ratio
79.6%
Financial strength
Net profit 2024
SEK 140
-100% vs 2023
| Revenue | — | — |
| EBITDA | SEK -97K | -17% |
| Net profit | SEK 140 | -100% |
| Total assets | SEK 617K | -10% |
| Equity | SEK 491K | +0% |
| Employees | 0 | — |
Legal name
Delavaran Group AB
Org number
5568799646
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
9 januari 2012
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget skall vara internationellt verksamt och erbjuda, bedriva, utföra samt förmedla medicinska behandlingar, inkluderande kosmetiskt relaterade ingrepp, och medicinska konsultverksamhet inom hälso- och sjukvård, där legitimerad och/eller specialiserad läkarkompetens krävs eller kan delegreras, samt idka annan därmed förenlig verksamhet. Bolaget skall även förvärva och förvalta värdepapper, andra finansiella instrument, fast egendom och annan därmed förenlig verksamhet.
Address
Email
lina@accountable.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 90 | 232 | 0 | 0 | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | −31 | 146 | −45 | −83 | −97 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | −31 | 146 | −45 | −83 | −97 |
| Net financials | −10 | — | 1 | 8 | 7 |
| Profit before tax | −2 | 105 | −44 | 70 | 9 |
| Tax | −3 | −26 | −0 | −13 | −9 |
| Net profit | −5 | 79 | −44 | 57 | 0 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 056 | 860 | 773 | 689 | 617 |
| Equity | 699 | 478 | 434 | 491 | 491 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 84 | 67 | 25 | 29 | 57 |
| Total debt | 84 | 67 | 25 | 29 | 57 |
EBITDA margin
-9744000.0%
This company
15.8%
Market median
-61670986% vs market
20202024
Equity ratio
79.6%
This company
38.2%
Market median
+108% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
14000.0%
This company
8.1%
Market median
+172740% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LH Liquidator | Liquidator | 2026 |
| Former (2) | ||
HD Chief Executive Officer | Chief Executive Officer | 2023 – 2023 |
SA Audit | Audit | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Deputy Board Member | 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Delavaran Group AB 
Delavaran Medical Consulting ABBoard members of Delavaran Group AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lina Helena Maria André Landgren | Liquidator | 0 companies |
| Hossein Delavaran | Chief Executive Officer | 0 companies |
| Stein Are Karlsen | Audit | 0 companies |
| Charlotte Mahsama Delavaran Shiraz | Board of Directors | 0 companies |
| Assall Fatima Delavaran | Deputy Board Member | 0 companies |